2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
2
Ovarian Neoplasms
1
Neoplasms
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Liver Neoplasms
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Anxiety Disorders
1
Interventions
pembrolizumab
186
Gemcitabine
170
Paclitaxel
152
Carboplatin
138
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
116
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
99
Fluorouracil
90
Capecitabine
86
Radiotherapy
81
Dexamethasone
81
Irinotecan
74
Standard of Care
69
Pemetrexed
69
Oxaliplatin
68
Drug Therapy
65
Leucovorin
64
Cetuximab
60
Erlotinib Hydrochloride
56
atezolizumab
53
Sorafenib
53
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Glutamyl Aminopeptidase
×
Clear all
NCT05441163
2025-06-24
ProActIF-01
Institut Curie
Phase NA
Recruiting
50 enrolled